# Mobile Powerhouses: Mitochondria Transfer via Tunnelling Nanotubes in Brain Health and Neurodegenerative Diseases

**Authors:** Anna Henrich, Hannah Scheiblich

PMC · DOI: 10.1111/ejn.70463 · 2026-03-19

## TL;DR

Mitochondria can move between brain cells through structures called tunnelling nanotubes, which may help with energy balance but also spread disease.

## Contribution

This paper highlights how tunnelling nanotubes mediate mitochondrial transfer in the brain and its implications for health and disease.

## Key findings

- Mitochondria transfer via tunnelling nanotubes supports bioenergetic recovery and immune modulation in the brain.
- Glial cells transfer mitochondria to stressed neurons, aiding in quality control and metabolic balance.
- TNT-mediated transfer can also spread pathological proteins and support tumor growth.

## Abstract

Mitochondria are central regulators of cellular metabolism, calcium homeostasis and survival. Owing to the brain's exceptional energy demand, mitochondrial dysfunction is tightly linked to neurodegenerative and neuroinflammatory disorders. Recent evidence challenges the traditional view of mitochondria as strictly cell‐autonomous organelles, revealing that they can be exchanged between cells via intercellular transfer by extracellular vesicles, gap junctions or tunnelling nanotubes (TNTs) as part of an adaptive mechanism of metabolic support and signalling. Among the pathways mediating this intercellular exchange, TNTs—thin, actin‐rich cytoplasmic bridges—have emerged as key conduits for mitochondrial transfer in the nervous system. TNTs enable bidirectional exchange of mitochondria between neurons, glia and vascular cells, thereby promoting bioenergetic recovery after injury and modulating immune and inflammatory responses. This review summarizes current evidence for TNT‐mediated mitochondrial transfer in the brain and highlights the underlying molecular mechanisms that coordinate mitochondrial movement, including cytoskeletal dynamics, mitochondrial trafficking machinery and stress‐induced signalling cascades. While mitochondrial donation can restore metabolic balance and promote neuroprotection, it may also facilitate the spread of pathological proteins, contributing to disease progression. Understanding the underlying molecular mechanism of TNT‐mediated mitochondrial transfer provides a new framework for exploring metabolic communication and cellular resilience in the brain. By emphasizing emerging conceptual and mechanistic insights, we outline how advancing this field could pave the way for the development of innovative therapeutic strategies for neurodegenerative and neuroinflammatory disorders.

Within the brain microenvironment, mitochondria are preferentially transferred from glial cells to metabolically stressed neurons via tunnelling nanotubes (TNTs). This intercellular exchange restores bioenergetic homeostasis and contributes to mitochondrial quality control through transmitophagy. In contrast, malignant cells can hijack TNT‐mediated mitochondrial transfer to fuel metabolic reprogramming, promote tumour growth and drive chemoresistance.

## Full-text entities

- **Genes:** TRAK2 (trafficking kinesin protein 2) [NCBI Gene 66008] {aka ALS2CR3, CALS-C, GRIF-1, GRIF1, MILT2, OIP98}, FLNC (filamin C) [NCBI Gene 2318] {aka ABP-280, ABP280A, ABPA, ABPL, ARVC15, CMD1PP}, MYO10 (myosin X) [NCBI Gene 4651] {aka MyoX}, STING1 (stimulator of interferon response cGAMP interactor 1) [NCBI Gene 340061] {aka ERIS, MITA, MPYS, NET23, SAVI, STING}, MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}, MYO19 (myosin XIX) [NCBI Gene 80179] {aka MYOHD1}, Tnnt3 (troponin T3, fast skeletal type) [NCBI Gene 24838] {aka Tnt}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, AKR1A1 (aldo-keto reductase family 1 member A1) [NCBI Gene 10327] {aka ALDR1, ALR, ARM, DD3, HEL-S-6}, MYH10 (myosin heavy chain 10) [NCBI Gene 4628] {aka NMMHC-IIB, NMMHCB}, Rhot1 (ras homolog family member T1) [NCBI Gene 59040] {aka 2210403N23Rik, Arht1, C430039G08Rik, Miro1}, RAB11A (RAB11A, member RAS oncogene family) [NCBI Gene 8766] {aka YL8}, RAB8A (RAB8A, member RAS oncogene family) [NCBI Gene 4218] {aka MEL, RAB8}, TNFAIP2 (TNF alpha induced protein 2) [NCBI Gene 7127] {aka B94, EXOC3L3}, ITPR3 (inositol 1,4,5-trisphosphate receptor type 3) [NCBI Gene 3710] {aka CMT1J, IMD132, IMD133, IP3R, IP3R-3, IP3R3}, NUCLEOLIN (nucleolin multifunctional protein) [NCBI Gene 4691] {aka C23, NCL, Nsr1}, GJA1 (gap junction protein alpha 1) [NCBI Gene 2697] {aka AVSD3, CMDR, CX43, EKVP, EKVP3, GJAL}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, Thbs1 (thrombospondin 1) [NCBI Gene 445442] {aka TSP-1, Tsp1}, TRAK1 (trafficking kinesin protein 1) [NCBI Gene 22906] {aka DEE68, EIEE68, MILT1, OIP106}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, CDC42 (cell division cycle 42) [NCBI Gene 998] {aka CDC42Hs, G25K, TKS}, CDH2 (cadherin 2) [NCBI Gene 1000] {aka ACOGS, ADHD8, ARVD14, CD325, CDHN, CDw325}, PRKN (parkin RBR E3 ubiquitin protein ligase) [NCBI Gene 5071] {aka AR-JP, LPRS2, PARK2, PDJ}, EPS8 (EGFR pathway substrate 8, signaling adaptor) [NCBI Gene 2059] {aka DFNB102}, SNCA (synuclein alpha) [NCBI Gene 6622] {aka NACP, PARK1, PARK4, PD1}, RALA (RAS like proto-oncogene A) [NCBI Gene 5898] {aka HINCONS, RAL}, ARRDC1 (arrestin domain containing 1) [NCBI Gene 92714], TNNT1 (troponin T1, slow skeletal type) [NCBI Gene 7138] {aka ANM, NEM5, STNT, TNT, TNTS}, LST1 (leukocyte specific transcript 1) [NCBI Gene 7940] {aka B144, D6S49E, LST-1}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56717] {aka 2610315D21Rik, FRAP, FRAP2, Frap1, RAFT1, RAPT1}, RHOA (ras homolog family member A) [NCBI Gene 387] {aka ARH12, ARHA, EDFAOB, RHO12, RHOH12}, HTT (huntingtin) [NCBI Gene 3064] {aka HD, IT15, LOMARS}, CFL1 (cofilin 1) [NCBI Gene 1072] {aka CFL, HEL-S-15, cofilin}, TFAM (transcription factor A, mitochondrial) [NCBI Gene 7019] {aka MTDPS15, MTTF1, MTTFA, TCF6, TCF6L1, TCF6L2}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, CD38 (CD38 molecule) [NCBI Gene 952] {aka ADPRC 1, ADPRC1, cADPR1}, ERP29 (endoplasmic reticulum protein 29) [NCBI Gene 10961] {aka C12orf8, ERp28, ERp31, HEL-S-107, PDI-DB, PDIA9}, CGAS (cyclic GMP-AMP synthase) [NCBI Gene 115004] {aka C6orf150, D4, MB21D1, h-cGAS}, RHOT2 (ras homolog family member T2) [NCBI Gene 89941] {aka ARHT2, C16orf39, MIRO-2, MIRO2, RASL}, PPIF (peptidylprolyl isomerase F) [NCBI Gene 10105] {aka CYP3, CyP-M, Cyp-D, CypD}, RAB35 (RAB35, member RAS oncogene family) [NCBI Gene 11021] {aka H-ray, RAB1C, RAY}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, PINK1 (PTEN induced kinase 1) [NCBI Gene 65018] {aka BRPK, PARK6}, APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}, Tnfaip2 (tumor necrosis factor, alpha-induced protein 2) [NCBI Gene 21928] {aka B94, Exoc3l3, M-sec, Tnfip2, tnfb94}, Tnnt1 (troponin T1, skeletal, slow) [NCBI Gene 21955] {aka Tnt, sTnT, ssTnT}
- **Diseases:** glioblastoma (MESH:D005909), hypoxia (MESH:D000860), brain (MESH:D001927), Cancer (MESH:D009369), stroke (MESH:D020521), cerebral ischemia (MESH:D002545), adenocarcinoma (MESH:D000230), disorders (MESH:D009358), Health (OMIM:603663), glioma (MESH:D005910), ischemic stroke (MESH:D002544), melanoma (MESH:D008545), traumatic brain injury (MESH:D000070642), Mitochondrial Dysfunction (MESH:D028361), neuronal loss (MESH:D009410), microvascular deficits (MESH:D017566), IP (MESH:D007184), ischemia (MESH:D007511), neuropathy (MESH:D009422), ischemic injury (MESH:D017202), inherited neurological conditions (MESH:D020271), mitochondrial failure (MESH:D051437), neurodegenerative (MESH:D019636), inflammation (MESH:D007249), Creutzfeldt-Jakob disease (MESH:D007562), toxicity (MESH:D064420), breast cancer (MESH:D001943), hypoxic (MESH:D002534), neurological disorders (MESH:D009461), lymph node metastasis (MESH:D008207), Lewy bodies (MESH:D020961), brain tumour (MESH:D001932), neurotoxic (MESH:D020258), mHTT (MESH:D016115), DNTs (MESH:D007635), PD (MESH:D010300), neuroinflammation (MESH:D000090862), ATP (OMIM:604273), AD (MESH:D000544)
- **Chemicals:** H2O2 (MESH:D006861), Oxygen (MESH:D010100), Rhodamine (MESH:D012235), calcium (MESH:D002118), cytochalasin D (MESH:D015638), Y-27632 (MESH:C108830), Ca2+ (-), ROS (MESH:D017382), cisplatin (MESH:D002945), lipids (MESH:D008055), glucose (MESH:D005947), ATP (MESH:D000255)
- **Species:** Human immunodeficiency virus 1 (no rank) [taxon 11676], Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** A549 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023), CAD — Mus musculus (Mouse), Transformed cell line (CVCL_0199), neuronal pheochromocytoma — Homo sapiens (Human), Hemimegalencephaly, Finite cell line (CVCL_3283), SH-SY5Y — Homo sapiens (Human), Neuroblastoma, Cancer cell line (CVCL_0019), STHdh^Q7/Q7 — Mus musculus (Mouse), Transformed cell line (CVCL_M590), BV2 — Mus musculus (Mouse), Transformed cell line (CVCL_0182), PC12 — Rattus norvegicus (Rat), Rat adrenal gland pheochromocytoma, Cancer cell line (CVCL_0481), BMSC — Oryctolagus cuniculus (Rabbit), Finite cell line (CVCL_B6BB)

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13003201/full.md

---
Source: https://tomesphere.com/paper/PMC13003201